aTyr Pharma, Inc.
ATYR
$3.10
$0.082.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | -- | 235.00K | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | -- | 235.00K | 0.00 |
| Cost of Revenue | 12.23M | 14.81M | 13.97M | 13.36M | 12.76M |
| Gross Profit | -12.23M | -14.81M | -13.97M | -13.13M | -12.76M |
| SG&A Expenses | 3.59M | 3.34M | 3.34M | 3.51M | 3.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.82M | 18.14M | 17.32M | 16.87M | 15.96M |
| Operating Income | -15.82M | -18.14M | -17.32M | -16.64M | -15.96M |
| Income Before Tax | -14.97M | -17.26M | -16.31M | -15.49M | -14.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.97M | -17.26M | -16.31M | -15.49M | -14.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.00K | 2.00K | -- | -4.00K | 1.00K |
| Net Income | -14.97M | -17.26M | -16.31M | -15.49M | -14.76M |
| EBIT | -15.82M | -18.14M | -17.32M | -16.64M | -15.96M |
| EBITDA | -15.65M | -17.97M | -17.14M | -16.46M | -15.78M |
| EPS Basic | -0.18 | -0.23 | -0.23 | -0.23 | -0.25 |
| Normalized Basic EPS | -0.11 | -0.14 | -0.14 | -0.15 | -0.16 |
| EPS Diluted | -0.18 | -0.23 | -0.23 | -0.23 | -0.25 |
| Normalized Diluted EPS | -0.11 | -0.14 | -0.14 | -0.15 | -0.16 |
| Average Basic Shares Outstanding | 82.72M | 75.80M | 72.28M | 66.08M | 59.26M |
| Average Diluted Shares Outstanding | 82.72M | 75.80M | 72.28M | 66.08M | 59.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |